A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer
Completed · Phase 1 · NCT03639194
Conditions: Small Cell Lung Cancer
At a glance
- Research payments reported, 2025
- $102,504
- U.S. investigators named
- 5
- Sites paid
- 5
- Planned or actual enrollment
- 132
About the trial
- Sponsor
- AbbVie
- Tested
- ABBV-011 (drug), Budigalimab (drug)
- Dates
- Started 2018-10-24; completion 2024-01-25
- Results posted
- Not yet
This is a multicenter, open-label, Phase 1 study of ABBV-011 given as a single agent and in combination with budigalimab (ABBV-181) in participants with relapsed or refractory small cell lung cancer (SCLC). The study consists of 4 parts: Part A is a single-agent ABBV-011 dose regimen finding cohort; followed by Part B, a single-agent ABBV-011 dose expansion cohort; and then Part C, an ABBV-011 and budigalimab (ABBV-181) combination escalation and expansion cohort; Part D, single-agent ABBV-011 dose-evaluating cohort for Japan.
From ClinicalTrials.gov, last updated 2024-02-09. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $102,504 in research payments for this study in 2025 (10 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Eric S. Schaefer, M.D. Hematology & Oncology · Rogers, AR
- Noura Choudhury, M.D. Medical Oncology · Chicago, IL
- Daniel Morgensztern, MD Medical Oncology · Saint Louis, MO
- Neal E. Ready, MD Medical Oncology · Durham, NC
- Wallace L. Akerley III, MD Medical Oncology · Salt Lake City, UT
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Memorial Sloan Kettering Cancer Center $63,372
- Duke University $24,882
- Highlands Oncology Group $8,980
- University of Utah Hospital and Clinics, UT $4,815
- Washington University in St Louis $454
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.